UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdi ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2023 Earnings Call Transcript August 2, 2023 8:30 AM ET Company Participants George Elston - Chief Financial Officer Dr. Jay Duker - President, and Chief Executive Officer Conference Call Participants Tyler Van Buren - Cowen Yatin Suneja - Guggenheim Jennifer Kim - Cantor Fitzgerald Colleen Kusy - Baird Daniel Catalin - Chardan Sean Kim - Jones Trading I-Eh Jen - Laidlaw & Co Chaitanya Gollakota - H.C. Wainwright Operator Good morning. My name is [indiscernibl ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2023 Results Conference Call May 3, 2023 8:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker - Chief Executive Officer Dr. Jay Duker - President and Chief Operating Officer Scott Jones - Chief Commercial Officer Conference Call Participants Yatin Suneja - Guggenheim Tyler Van Buren - Cowen Jennifer Kim - Cantor Fitzgerald Colleen Kusy - Baird Daniel Catalin - Chardan I-Eh Jen - Laidlaw & Co Chaitanya Gollakota - H.C. Wainwright ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 480 Pleasant Street Watertown, MA (Address of principal executive offices) 26-2774444 (I.R.S. Employer Identification No.) 02472 (Zip Code) ☐ TRANSITION REPORT PURS ...

Financial Performance - Product sales increased by $4.6 million, or 13%, to $39.9 million in 2022 compared to $35.3 million in 2021, driven by a return of customer demand as procedures resumed [457]. - License and collaboration agreement revenues decreased by $394,000, or 52%, to $362,000 in 2022, primarily due to reduced revenue from Ocumension for technical assistance [460]. - Royalty income increased by $266,000, or 31%, to $1.1 million in 2022, attributed to Ocumension royalties of $269,000 [461]. - The company recorded a total revenue of $41.4 million in 2022, an increase of $4.5 million, or 12%, from $36.9 million in 2021 [457]. - The net loss for 2022 was $102.3 million, compared to a net loss of $58.4 million in 2021, representing an increase of $43.8 million, or 75% [457]. - Total operating expenses increased by $48.8 million, or 53%, to $141.0 million in 2022, with significant contributions from impairment of acquired intangible assets [457]. - General and administrative expenses increased by $9.2 million, or 36%, to $34.8 million for 2022 from $25.6 million for the prior year [465]. - Research and development expenses rose by $21.1 million, or 74%, to $49.6 million in 2022, mainly due to personnel costs and increased clinical trial expenses [463]. Regulatory and Clinical Developments - The FDA has updated regulatory requirements for combination drug/device products, necessitating additional clinical trials for YUTIQ 50, leading to increased program costs and a pause in enrollment for the clinical trial [428]. - EYP-1901 is currently in Phase 2 clinical trials for wet AMD, with initial top-line data expected in the second half of 2023 [428]. - The twelve-month DAVIO Phase 1 clinical trial data for EYP-1901 showed a treatment burden reduction of 75% at six months and 73% at twelve months [428]. - YUTIQ 0.18mg was approved by China's CDE for the treatment of posterior segment uveitis in June 2022 [426]. Cash Flow and Financing - Cash, cash equivalents, and investments in marketable securities totaled $144.6 million as of December 31, 2022, expected to fund operations into the second half of 2024 [478]. - Operating cash outflows for the year ended December 31, 2022 totaled $65.0 million, primarily due to a net loss of $102.3 million [482]. - Net cash used in investing activities for 2022 was $17.3 million, compared to $33.1 million in 2021 [484]. - The company entered into a loan agreement with Silicon Valley Bank providing for a senior secured term loan facility of $30.0 million and a revolving credit facility of up to $15.0 million [472]. - The repayment of loans under the Credit Facilities is due on January 1, 2027, with interest rates based on the Wall Street Journal prime rate plus a margin [473]. - Net cash used in financing activities for fiscal 2022 totaled $690,000 [485]. - $38.2 million was used to pay off the CRG loan in fiscal 2022 [485]. Market and Operational Impact - The fiscal year ended December 31, 2022, was impacted by a reduction in physician office visits due to the ongoing pandemic, adversely affecting YUTIQ sales, particularly in early 2022 [426]. - Customer demand for YUTIQ in Q4 2022 increased by 11% compared to Q3 2022, while demand for DEXYCU decreased by 70% due to the loss of pass-through coverage by CMS [433]. - The company received a subpoena from the U.S. Attorney's Office regarding sales and marketing practices, which may have a material adverse effect on its business [428]. - Sales and marketing expenses decreased by $2.0 million, or 7%, to $25.5 million in 2022, mainly due to lower promotional activities for DEXYCU [464]. - Impairment of acquired intangible assets amounted to $20.7 million in Q4 2022, related to the DEXYCU technology [456]. Debt and Interest - Interest expense totaled $3.2 million for 2022, down from $5.5 million in 2021 due to a lower interest rate on the SVB Loan [467]. - Interest income from investments in marketable securities increased to $2.1 million for fiscal 2022 compared to $292,000 in the prior year [468]. - The total accumulated deficit reached $671.3 million as of December 31, 2022, with operations financed primarily through equity sales and debt issuance [470]. Company Structure and Reporting - The company does not have any off-balance sheet arrangements that would materially affect financial conditions [486]. - The company is classified as a smaller reporting company and is not required to provide certain market risk disclosures [487].

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Nancy Lurker - CEO George O. Elston - CFO Jay Duker - President and COO Scott Jones - Chief Commercial Officer Conference Call Participants Unidentified Analyst - Guggenheim Securities Georgi Yordanov - Cowen Jennifer Kim - Cantor Fitzgerald Yale Jen - Laidlaw & Company Yi Chen - H.C. Wainwright Operator Good day and welcome to the EyePoint Pharmaceuticals Fourth Quarter and Full Year ...

EYEPOINT® PHARMACEUTICALS Investor Presentation November 2022 Forward-Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expecta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 EYPT The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ CO ...

Start Time: 08:30 January 1, 0000 9:13 AM ET EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2022 Earnings Conference Call November 02, 2022, 08:30 AM ET Company Participants Nancy Lurker - President and CEO George Elston - CFO Jay Duker - COO Scott Jones - Chief Commercial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Georgi Yordanov - Cowen Yi Chen - H.C. Wainwright Yale Jen - Laidlaw & Company Daniil Gatualin - Chardan Yuan Zhi - B. Riley Operator Welcome to the EyePoint Third Qua ...

9 EYEPOINT® PHARMACEUTICALS Investor Presentation September 28, 2022 Forward-Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our ...